Does the addition of spironolactone to an ACE inhibitor or AngII receptor blocker improve proteinuria, blood pressure, and renal function in patients with type 2 diabetic nephropathy?
Adding spironolactone to ACEi/ARB therapy in type 2 diabetic nephropathy provides a marked antiproteinuric effect, though this is partly related to a reduction in GFR.
Addition of spironolactone to an ACE inhibitor or AngII receptor blocker is associated with a marked and sustained antiproteinuric effect, which in part relates to the more pronounced reduction in GFR.
Meiracker et al. (Wed,) studied this question.